Veracyte Inc VCYT:NASDAQ

Last Price$29.18NASDAQ Previous Close - Last Trade as of 4:00PM ET 12/06/19

Today's Change-0.81(2.70%)
Bid (Size)$29.18 (16)
Ask (Size)$29.22 (18)
Day Low / High$29.13 - 30.61
Volume527.0 K
 

View Biotechnology IndustryPeer Comparison as of 12/06/2019

 

Veracyte Inc ( NASDAQ )

Price: $29.18
Change: -0.81 (2.70%)
Volume: 527.0 K
4:00PM ET 12/06/2019
 
 

Arvinas Inc ( NASDAQ )

Price: $38.42
Change: +0.66 (1.75%)
Volume: 271.8 K
4:00PM ET 12/06/2019
 
 

Epizyme Inc ( NASDAQ )

Price: $18.22
Change: +2.92 (19.08%)
Volume: 2.4 M
4:00PM ET 12/06/2019
 
 

Editas Medicine Inc ( NASDAQ )

Price: $30.92
Change: +0.53 (1.74%)
Volume: 1.1 M
4:00PM ET 12/06/2019
 
 

NextCure Inc ( NASDAQ )

Price: $50.27
Change: +0.35 (0.70%)
Volume: 303.1 K
4:00PM ET 12/06/2019
 

Read more news Recent News

Insider Trends: Insider at Veracyte Converts/Exercises Derivative Security, Sells for Taxes and Self, Buying Trend Remains Intact
4:24PM ET 12/04/2019 MT Newswires

On Dec 02, 2019, Chief Scientific & Med Officer, Dr Giulia C Kennedy, exercised options/derivative securities for 15,032 shares. A portion of these...

Veracyte Buys NanoString nCounter Platform for Diagnostic Use for $50 Million in Cash and Stock Deal
5:16PM ET 12/03/2019 MT Newswires

Veracyte (VCYT) said on Tuesday it has acquired an exclusive global license to NanoString's (NSTG) nCounter platform for diagnostic use to expand its...

Veracyte Q3 Results Beat Expectations
5:07PM ET 10/22/2019 MT Newswires

Veracyte (VCYT) on Tuesday reported a $0.02 loss per share for Q3, down from $0.12 loss per share in the year-ago period, beating Capital IQ estimate of...

Veracyte's Noninvasive Nasal Swab Test Shows Accurate Classification of Lung Cancer Risk in Patients With Lung Nodules
3:15PM ET 10/22/2019 MT Newswires

Veracyte (VCYT) said Tuesday its noninvasive nasal swab test's preliminary clinical data showed an accurate classification of lung cancer risk in patients...

View all Commentary and Analysis

Veracyte, Inc. 2019 Q3 - Results - Earnings Call Presentation
12:37AM ET 10/23/2019 Seeking Alpha

Veracyte, Inc. (VCYT) CEO Bonnie Anderson on Q3 2019 Earnings Call Transcript
12:36AM ET 10/23/2019 Seeking Alpha

Fiera Capital SMID Cap Growth Strategy Q3 2019 Commentary
11:45AM ET 10/21/2019 Seeking Alpha

Veracyte: Exceeding Expectations In Genomic Testing
10:05AM ET 9/30/2019 Seeking Alpha

Company Profile

Business DescriptionVeracyte, Inc. engages in the research, development, and commercialization of diagnostic products. Its portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA. View company web site for more details
Address6000 Shoreline Court
South San Francisco, California 94080
Phone+1.650.243.6300
Number of Employees270
Recent SEC Filing12/04/20194
Chairman & Chief Executive OfficerBonnie H. Anderson
Chief Operating & Financial OfficerKeith Kennedy
Chief Scientific & Medical OfficerGiulia C. Kennedy
Chief Information OfficerAshish Kheterpal

Company Highlights

Price Open$30.50
Previous Close$29.99
52 Week Range$10.72 - 31.18
Market Capitalization$1.4 B
Shares Outstanding48.8 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement02/24/2020

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$0.19
Beta vs. S&P 500N/A
Revenue$92.0 M
Net Profit Margin-7.08%
Return on Equity-5.33%

Analyst Ratings as of 07/31/2019

Buy
6
Overweight
0
Hold
0
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset